Facebook-f Tiktok Instagram Youtube Whatsapp Linkedin
Facebook-f Tiktok Instagram Youtube Whatsapp Linkedin
All Medical Experts

Doctor Profile

Oncology Center

Dr. Wei Xue

Prostate Oncology

Professor · Chief Physician · Doctoral Supervisor · MD

Dr. Xue is vice president of Renji Hospital, Shanghai Jiao Tong University School of Medicine; standing member of the Urology Branch of Chinese Medical Association; vice chair of the Youth Committee of Chinese Urological Association (CUA); director of the Clinical Quality Control Committee for Urology of Shanghai Municipal Health Commission; chair of the Urology Branch of Shanghai Medical Association.

Genitourinary Tumors

Prostate Cancers

Kidney Cancers

RALS Expert

30+yrs

Experience

1200+

Da Vinci Robotic Surgeries

100+

SCI Papers

Expertise

Dr. Xue specializes in the diagnosis and treatment of complex urological diseases, with a focus on surgical management and comprehensive care of prostate cancer. He was the first in China to perform a Da Vinci robot-assisted radical prostatectomy and has been a key advocate for day surgery practices. He also successfully performed China’s first Da Vinci robot-assisted radical prostatectomy combined with extended pelvic lymph node dissection using fluorescence imaging technology. His team has developed a robotic system for retrograde intrarenal surgery via the ureter, enhancing surgical precision and patient comfort.

Professional Background

Dr. Xue has been engaged in clinical and basic research on genitourinary tumors, with a particular focus on prostate cancer, for more than 30 years, having performed over 1200 robot-assisted laparoscopic surgeries. Dr. Xue has led the development of China’s first urology-specific AI assistant based on structured data. The system can conduct automated consultations, interpret diagnostic results, and provide medical insurance guidance. Within 8 months of launch, it served over 300,000 patients and handled more than 600,000 Q&A sessions, offering automated clinical support at scale.

Awards & Honors

  • First Prize of Outstanding Scientific Research Achievements in Institutions of Higher Education, Ministry of Education
  • First Prize of Shanghai Municipal Scientific and Technological Progress Award
  • First Prize of the Shanghai Medical Science and Technology Award
  • Recepient of the Baosteel Education Award
  • Recognized as a Leading Talent of Shanghai
  • Outstanding Academic Leader of Shanghai

Recent Key Publications:

  1. Wang X , Shi A , Liu J ,et al.CDCA5-EEF1A1 interaction promotes progression of clear cell renal cell carcinoma by regulating mTOR signaling[J].Cancer Cell International, 2024, 24(1).DOI:10.1186/s12935-024-03330-4.

  2. Wang Y , Qian H , Shao X ,et al.Multimodal convolutional neural networks based on the Raman spectra of serum and clinical features for the early diagnosis of prostate cancer[J].Spectrochimica acta, Part A. Molecular and biomolecular spectroscopy, 2023.DOI:10.1016/j.saa.2023.122426.

  3. Jin D , Qian L , Xia J ,et al.In vivo detection demonstrates circulating tumor cell reduction instead of baseline number has prognostic value in bladder cancer patients receiving neoadjuvant chemotherapy[J].Cellular Oncology (2211-3428), 2023, 46(3).DOI:10.1007/s13402-023-00785-x.

  4. Wu X , Zhou J , Chen W ,et al.Retroperitoneoscopic Clampless, Sutureless Hybrid Therapy in the Management of Renal Hilar Tumors[J].Annals of Surgical Oncology: An Oncology Journal for Surgeons, 2024, 31(1).DOI:10.1245/s10434-023-14248-y.

  5. Xiaorong W , Jiale Z , Wei C ,et al.ASO Visual Abstract: Retroperitoneoscopic?Clampless?Sutureless?Hybrid Therapy in the Management of Renal Hilar Tumors[J].Annals of surgical oncology, 2024(1):31.DOI:10.1245/s10434-023-14385-4.

  6. Liu G , Pan S , Zhao R ,et al.The added value of AI-based computer-aided diagnosis in classification of cancer at prostate MRI[J].European radiology, 2023.DOI:10.1007/s00330-023-09433-2.

  7. Wang J , Du X , Wang X ,et al.Tumor-derived miR-378a-3p-containing extracellular vesicles promote osteolysis by activating the Dyrk1a/Nfatc1/Angptl2 axis for bone metastasis[J].Cancer Letters, 2022, 526:76-90.DOI:10.1016/j.canlet.2021.11.017.

  8. Zhou J , Wang J , Kong W ,et al.VHL and DNA damage repair pathway alterations as potential clinical biomarkers for first-line TKIs in metastatic clear cell renal cell carcinomas[J].Cellular oncology, 2022.DOI:10.1007/s13402-022-00691-8.

  9. Wei X , Zhu L , Zeng Y ,et al.Detection of prostate cancer using diffusion-relaxation correlation spectrum imaging with support vector machine model – a feasibility study[J].Cancer imaging : the official publication of the International Cancer Imaging Society, 2022, 22(1):77.DOI:10.1186/s40644-022-00516-9.

  10. Wang H , Xue W , Yan W ,et al.Extended Focal Ablation of Localized Prostate Cancer With High-Frequency Irreversible Electroporation: A Nonrandomized Controlled Trial[J].JAMA surgery, 2022, 157(8):693-700.DOI:10.1001/jamasurg.2022.2230.

  11. Hu G , Ma J , Zhang J ,et al.Hypoxia-induced lncHILAR promotes renal cancer cell invasion and metastasis via ceRNA for the miR-613/206/1-1-3p/Jagged-1/Notch/CXCR4 signaling pathway[J].Molecular Therapy, 2021.DOI:10.1016/j.ymthe.2021.05.020.

  12. Shangguan X , He J , Ma Z ,et al.SUMOylation controls the binding of hexokinase 2 to mitochondria and protects against prostate cancer tumorigenesis[J].Nature Communications, 2021, 12(1).DOI:10.1038/s41467-021-22163-7.

  13. Wang Y , Fang Y X , Dong B ,et al.Discovery of extracellular vesicles derived miR-181a-5p in patient’s serum as an indicator for bone-metastatic prostate cancer[J].Theranostics, 2021, 11(2):878-892.DOI:10.7150/thno.49186.

  14. Xu F , Shangguan X , Pan J ,et al.HOXD13 Suppresses Prostate Cancer Metastasis and BMP4﹊nduced EMT by Inhibiting SMAD1[J].International Journal of Cancer, 2021.DOI:10.1002/ijc.33494.

  15. Chen H , Zhang R , Xie F ,et al.90P Longitudinal circulating tumor DNA profiling of metastatic urothelial carcinoma in the POLARIS-03 trial[J].Annals of Oncology, 2021, 32:S395-.DOI:10.1016/j.annonc.2021.08.370.

  16. Zhai W , Wang J , He N ,et al.DNA damage repair (DDR) pathway alteration in advanced renal cell carcinoma (RCC) is association with good progression-free survival with tyrosine kinase inhibitor (TKI) therapy.[J].Journal of Clinical Oncology, 2021, 39(6_suppl):346-346.DOI:10.1200/JCO.2021.39.6_suppl.346.

  17. Fan L , Fei X , Dong B ,et al.Genomic analysis of castration sensitive and resistant prostate cancer patients by multiple-gene targeted sequencing[J].Journal of Clinical Oncology, 2020, 38(15_suppl):e17525-e17525.DOI:10.1200/JCO.2020.38.15_suppl.e17525.

  18. Guo J , Yu Z , Yan W ,et al.Two‐stage degradation in n‐channel LTPS‐TFTs under negative and positive bias stresses[J].Journal of the Society for Information Display, 2020, 28(9).DOI:10.1002/jsid.873.

  19. Dong L , Zhang Z , Smith K ,et al.The combination of size‐based separation and selection‐free technology provides higher circulating tumour cells detection sensitivity than either method alone in patients with metastatic prostate cancer[J].BJU International, 2020.DOI:10.1111/bju.15041.

  20. Cang S , Li Y , Xue W ,et al.Conservative chaos and invariant tori in the modified Sprott A system[J].Nonlinear Dynamics, 2020, 99(2):1699-1708.DOI:10.1007/s11071-019-05385-9.

Book Appointment

Contact Us

We would love to speak with you.
Feel free to reach out using the below details.

Find us Here

  • +1 8324667523
  • services@chinahealthtrip.com

Fill out the form below!

Oncology Center

Doctor Profile

Dr. Wei Xue

Prostate Oncology

Professor · Chief Physician · Doctoral Supervisor · MD

Genitourinary Tumors

Prostate Cancers

Kidney Cancers

RALS Expert

Experience

0 +yrs
0 +

Surgeries

0 +

SCI Papers

Second Opinion ＄399

Contact Me

Expertise

Dr. Xue specializes in the diagnosis and treatment of complex urological diseases, with a focus on surgical management and comprehensive care of prostate cancer. He was the first in China to perform a Da Vinci robot-assisted radical prostatectomy and has been a key advocate for day surgery practices. He also successfully performed China’s first Da Vinci robot-assisted radical prostatectomy combined with extended pelvic lymph node dissection using fluorescence imaging technology. His team has developed a robotic system for retrograde intrarenal surgery via the ureter, enhancing surgical precision and patient comfort.

Professional Background

Dr. Xue has been engaged in clinical and basic research on genitourinary tumors, with a particular focus on prostate cancer, for more than 30 years, having performed over 1200 robot-assisted laparoscopic surgeries. Dr. Xue has led the development of China’s first urology-specific AI assistant based on structured data. The system can conduct automated consultations, interpret diagnostic results, and provide medical insurance guidance. Within 8 months of launch, it served over 300,000 patients and handled more than 600,000 Q&A sessions, offering automated clinical support at scale.

Awards & Honors

First Prize of Outstanding Scientific Research Achievements in Institutions of Higher Education, Ministry of Education

First Prize of Shanghai Municipal Scientific and Technological Progress Award

First Prize of the Shanghai Medical Science and Technology Award

Recepient of the Baosteel Education Award

Recognized as a Leading Talent of Shanghai

Outstanding Academic Leader of Shanghai

Professional Background

  1. Wang X , Shi A , Liu J ,et al.CDCA5-EEF1A1 interaction promotes progression of clear cell renal cell carcinoma by regulating mTOR signaling[J].Cancer Cell International, 2024, 24(1).DOI:10.1186/s12935-024-03330-4.
  2. Wang Y , Qian H , Shao X ,et al.Multimodal convolutional neural networks based on the Raman spectra of serum and clinical features for the early diagnosis of prostate cancer[J].Spectrochimica acta, Part A. Molecular and biomolecular spectroscopy, 2023.DOI:10.1016/j.saa.2023.122426.
  3. Jin D , Qian L , Xia J ,et al.In vivo detection demonstrates circulating tumor cell reduction instead of baseline number has prognostic value in bladder cancer patients receiving neoadjuvant chemotherapy[J].Cellular Oncology (2211-3428), 2023, 46(3).DOI:10.1007/s13402-023-00785-x.
  4. Wu X , Zhou J , Chen W ,et al.Retroperitoneoscopic Clampless, Sutureless Hybrid Therapy in the Management of Renal Hilar Tumors[J].Annals of Surgical Oncology: An Oncology Journal for Surgeons, 2024, 31(1).DOI:10.1245/s10434-023-14248-y.
  5. Xiaorong W , Jiale Z , Wei C ,et al.ASO Visual Abstract: Retroperitoneoscopic?Clampless?Sutureless?Hybrid Therapy in the Management of Renal Hilar Tumors[J].Annals of surgical oncology, 2024(1):31.DOI:10.1245/s10434-023-14385-4.
  6. Liu G , Pan S , Zhao R ,et al.The added value of AI-based computer-aided diagnosis in classification of cancer at prostate MRI[J].European radiology, 2023.DOI:10.1007/s00330-023-09433-2.
  7. Wang J , Du X , Wang X ,et al.Tumor-derived miR-378a-3p-containing extracellular vesicles promote osteolysis by activating the Dyrk1a/Nfatc1/Angptl2 axis for bone metastasis[J].Cancer Letters, 2022, 526:76-90.DOI:10.1016/j.canlet.2021.11.017.
  8. Zhou J , Wang J , Kong W ,et al.VHL and DNA damage repair pathway alterations as potential clinical biomarkers for first-line TKIs in metastatic clear cell renal cell carcinomas[J].Cellular oncology, 2022.DOI:10.1007/s13402-022-00691-8.
  9. Wei X , Zhu L , Zeng Y ,et al.Detection of prostate cancer using diffusion-relaxation correlation spectrum imaging with support vector machine model – a feasibility study[J].Cancer imaging : the official publication of the International Cancer Imaging Society, 2022, 22(1):77.DOI:10.1186/s40644-022-00516-9.
  10. Wang H , Xue W , Yan W ,et al.Extended Focal Ablation of Localized Prostate Cancer With High-Frequency Irreversible Electroporation: A Nonrandomized Controlled Trial[J].JAMA surgery, 2022, 157(8):693-700.DOI:10.1001/jamasurg.2022.2230.
  11. Hu G , Ma J , Zhang J ,et al.Hypoxia-induced lncHILAR promotes renal cancer cell invasion and metastasis via ceRNA for the miR-613/206/1-1-3p/Jagged-1/Notch/CXCR4 signaling pathway[J].Molecular Therapy, 2021.DOI:10.1016/j.ymthe.2021.05.020.
  12. Shangguan X , He J , Ma Z ,et al.SUMOylation controls the binding of hexokinase 2 to mitochondria and protects against prostate cancer tumorigenesis[J].Nature Communications, 2021, 12(1).DOI:10.1038/s41467-021-22163-7.
  13. Wang Y , Fang Y X , Dong B ,et al.Discovery of extracellular vesicles derived miR-181a-5p in patient’s serum as an indicator for bone-metastatic prostate cancer[J].Theranostics, 2021, 11(2):878-892.DOI:10.7150/thno.49186.
  14. Xu F , Shangguan X , Pan J ,et al.HOXD13 Suppresses Prostate Cancer Metastasis and BMP4﹊nduced EMT by Inhibiting SMAD1[J].International Journal of Cancer, 2021.DOI:10.1002/ijc.33494.
  15. Chen H , Zhang R , Xie F ,et al.90P Longitudinal circulating tumor DNA profiling of metastatic urothelial carcinoma in the POLARIS-03 trial[J].Annals of Oncology, 2021, 32:S395-.DOI:10.1016/j.annonc.2021.08.370.
  16. Zhai W , Wang J , He N ,et al.DNA damage repair (DDR) pathway alteration in advanced renal cell carcinoma (RCC) is association with good progression-free survival with tyrosine kinase inhibitor (TKI) therapy.[J].Journal of Clinical Oncology, 2021, 39(6_suppl):346-346.DOI:10.1200/JCO.2021.39.6_suppl.346.
  17. Fan L , Fei X , Dong B ,et al.Genomic analysis of castration sensitive and resistant prostate cancer patients by multiple-gene targeted sequencing[J].Journal of Clinical Oncology, 2020, 38(15_suppl):e17525-e17525.DOI:10.1200/JCO.2020.38.15_suppl.e17525.
  18. Guo J , Yu Z , Yan W ,et al.Two‐stage degradation in n‐channel LTPS‐TFTs under negative and positive bias stresses[J].Journal of the Society for Information Display, 2020, 28(9).DOI:10.1002/jsid.873.
  19. Dong L , Zhang Z , Smith K ,et al.The combination of size‐based separation and selection‐free technology provides higher circulating tumour cells detection sensitivity than either method alone in patients with metastatic prostate cancer[J].BJU International, 2020.DOI:10.1111/bju.15041.
  20. Cang S , Li Y , Xue W ,et al.Conservative chaos and invariant tori in the modified Sprott A system[J].Nonlinear Dynamics, 2020, 99(2):1699-1708.DOI:10.1007/s11071-019-05385-9.

Contact Us

We would love to speak with you.
Feel free to reach out using the below details.

Find us Here

  • +1 8324667523
  • services@chinahealthtrip.com

Fill out the form below!

WhatsApp

Book Your Appointment